Selank tracker
Educational reference for Selank. Use it inside TrackPep to log doses, side effects, and rotation sites.
Half-life
0.5 h
Tmax
0.25 h
Category
peptide
> PLACEHOLDER — pending clinical review by licensed pharmacist. Selank is a synthetic heptapeptide derived from tuftsin, an immunomodulatory fragment of IgG. It has been studied primarily in Russian literature for anxiolytic and immunomodulatory effects. The proposed mechanism involves modulation of the serotonin and dopamine systems as well as anti-inflammatory cytokine regulation. Its half-life is approximately 30 minutes. While not FDA-approved, selank is used in research and off-label contexts for anxiety and cognitive enhancement. Users should track dosing, subjective anxiety scores, and any side effects systematically.
Mechanism
A synthetic heptapeptide derived from the endogenous peptide tuftsin. In preclinical research it has been associated with anxiolytic and immunomodulatory effects, possibly involving GABAergic and enkephalin-related pathways; the mechanism in humans is not well characterized.
Research summary
Most research originates from a limited number of groups, largely preclinical or small studies, primarily in Russia where a related formulation has been used. It is not an FDA-approved drug, and independent modern clinical data are limited. Claims should be read against that evidence gap.
Dosing in the literature
Studies have used intranasal administration under research conditions. There is no FDA-approved regimen; this summary does not provide dosing.
Reported side effects
Controlled human safety data are limited, so the side-effect and long-term safety profile is largely unknown. Sourcing and purity are recurring quality concerns.
Stacking notes
Discussed anecdotally alongside Semax in nootropic contexts; there is no controlled human evidence supporting specific combinations.
Educational summary of published research. Not dosing guidance or medical advice.
Sources
- Selank anxiolytic peptide research overview · peer-reviewed articles (2011)largely single-region and preclinical evidence; search PubMed for Selank
- Regulatory status note · FDA / regulatory guidance (2024)not FDA-approved; verify current status
References
- Selank reviewDOI: 10.1007/s11055-014-9920-8
Track Selank in TrackPep
Reconstitution calculator, interactive body-map rotation, side-effect timeline, weight trends, and a private log — all in one place. Free to try.